苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

Learn More
Folded page of a newspaper

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

苹果软件-免费软件站-雷霆加器速-easylink加速器2025年

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

茄子加速器破解版,茄子加速器npv,茄子加速器2025,茄子加速器不能用了  灯塔加速器破解版,灯塔加速器官方网址,灯塔加速器pc版下载,灯塔加速器2025  猴王加速器破解版,猴王加速器官网网址,猴王加速器2025年,猴王加速器vqn  clash加速器下载官网,clash加速器下载打不开,clash加速器下载2025年,clash加速器下载打不开了  天行加速2025  极光vp n官网2025  快橙vp2025  旋风加速器官网2025